Favorable News Coverage Somewhat Unlikely to Affect Vascular Biogenics (NASDAQ:VBLT) Share Price
Media stories about Vascular Biogenics (NASDAQ:VBLT) have been trending positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Vascular Biogenics earned a media sentiment score of 0.26 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 46.0062293089039 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the news stories that may have impacted Accern Sentiment’s analysis:
- Vascular Biogenics Ltd. (VBLT) Scheduled to Post Earnings on Monday (americanbankingnews.com)
- Head to Head Review: Vascular Biogenics (VBLT) vs. MEI Pharma (MEIP) (americanbankingnews.com)
- Zacks: Brokerages Anticipate Vascular Biogenics Ltd. (VBLT) Will Post Earnings of -$0.17 Per Share (americanbankingnews.com)
- Neogen Corporation (NEOG) noted a price change of 0.00% and Vascular Biogenics Ltd. (VBLT) closes with a move of … – Stocks Gallery (stocksgallery.com)
- VBL Therapeutics to Report Second Quarter 2017 Results on August 14 (finance.yahoo.com)
Vascular Biogenics (NASDAQ:VBLT) remained flat at $4.15 during midday trading on Tuesday. The company’s stock had a trading volume of 78,913 shares. The company’s market capitalization is $111.66 million. Vascular Biogenics has a one year low of $3.80 and a one year high of $6.70. The firm has a 50 day moving average of $4.46 and a 200-day moving average of $5.29.
Vascular Biogenics (NASDAQ:VBLT) last announced its quarterly earnings results on Monday, May 15th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by $0.02. Analysts anticipate that Vascular Biogenics will post ($0.82) EPS for the current fiscal year.
Several brokerages recently commented on VBLT. Zacks Investment Research raised shares of Vascular Biogenics from a “sell” rating to a “hold” rating in a report on Wednesday, July 19th. ValuEngine lowered shares of Vascular Biogenics from a “hold” rating to a “sell” rating in a report on Tuesday, June 6th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $12.90.
About Vascular Biogenics
Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.
Receive News & Ratings for Vascular Biogenics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.